Loading...
Market
What will be the market share of AstraZeneca's benralizumab in the global asthma and COPD treatment market by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Industry reports and market analysis publications
Story
AstraZeneca's New Monoclonal Antibody Treatment Reduces Asthma and COPD Attacks by 30%
Nov 28, 2024, 10:20 AM
Researchers have developed the first new treatment for asthma and chronic obstructive pulmonary disease (COPD) attacks in 50 years, which has been hailed as a 'game-changer' by doctors and patients. The treatment involves an injection of benralizumab, a monoclonal antibody that targets the interleukin-5 receptor-α, showing greater efficacy than the current standard of steroid tablets. A phase II clinical trial conducted by King's College London demonstrated that this new treatment reduces the need for further treatment by 30% compared to steroids. This breakthrough, developed by AstraZeneca, could significantly impact the lives of millions, including the 2 million annual asthma attacks in the UK alone.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10 • 25%
10 to 20 • 25%
21 to 30 • 25%
More than 30 • 25%
Top 1 • 25%
Top 2-3 • 25%
Top 4-5 • 25%
Below Top 5 • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Less than 20% reduction • 25%
20% to 30% reduction • 25%
31% to 40% reduction • 25%
More than 40% reduction • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%